Ergoteles’s scPharmaceuticals SCPH Stock Holding History

Ergoteles’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-27,116	Closed	-$180K	–	1551
2021 Q3	$180K	Sell	27,116 -756	-3%	-$4.52K	0.01%	1033
2021 Q2	$170K	Buy	+27,872	New	+$168K	﹤0.01%	1327

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Ergoteles's SCPH Position: Q4 2021 in Review

Ergoteles sold out of scPharmaceuticals (SCPH) in Q4 2021, closing a stake of 27,116 shares — an estimated $180K sold.

Ergoteles first reported a position in SCPH in Q2 2021 and held it in 2 quarters. The position peaked at $180K in Q3 2021. 33 funds tracked by Wall St. Rank hold SCPH as of Q4 2021.

Ergoteles reported no remaining scPharmaceuticals position as of Q4 2021 after selling out during the quarter.
Ergoteles sold 27,116 scPharmaceuticals shares in Q4 2021, an estimated $180K.
Ergoteles first reported a position in scPharmaceuticals in Q2 2021 and held it in 2 quarters.
Ergoteles's scPharmaceuticals position peaked at $180K in Q3 2021.
33 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.